Pancreatic Cancer Pill Shows Promise

New drug nearly doubles overall survival time, drug company reports

Apr. 13, 2026 at 7:42pm

Got story updates? Submit your updates here. ›

A translucent, X-ray-like image of a human pancreas, with the internal structures glowing and highlighted to represent the targeted genetic mutations in a new cancer treatment.A new pancreatic cancer treatment pill targets specific genetic mutations, offering a potential breakthrough for one of the deadliest forms of the disease.Oklahoma City Today

A new pancreatic cancer treatment pill has been shown to nearly double the overall survival time for patients, according to the drug's manufacturer. The announcement comes as a potential breakthrough in the fight against one of the deadliest forms of cancer.

Why it matters

Pancreatic cancer has historically had very poor survival rates, with a 5-year survival rate of only around 10%. This new treatment could significantly improve outcomes for those diagnosed with this aggressive disease.

The details

The drug company behind the new pancreatic cancer pill claims the treatment has demonstrated a median overall survival time of nearly 2 years, compared to just over 1 year for standard of care. The pill works by targeting specific genetic mutations found in some pancreatic tumors.

  • The drug trial results were announced on April 13, 2026.

The players

Pancreatic Cancer Drug Manufacturer

The pharmaceutical company that developed and is testing the new pancreatic cancer treatment pill.

Got photos? Submit your photos here. ›

What they’re saying

“These results are extremely encouraging and represent a potential major advancement in the fight against pancreatic cancer.”

— Dr. Emily Walters, Chief Medical Officer

What’s next

The drug company plans to submit the treatment for FDA approval later this year, with the goal of making it available to patients as soon as possible.

The takeaway

This new pancreatic cancer pill could offer a glimmer of hope for patients facing one of the deadliest forms of the disease, potentially doubling their overall survival time if the promising trial results hold true.